These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 28468075

  • 21. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma.
    Köberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, Welker MW, Elhendawy M, Zeuzem S, Piiper A, Waidmann O.
    Eur J Cancer; 2013 Nov; 49(16):3442-9. PubMed ID: 23810247
    [Abstract] [Full Text] [Related]

  • 22. NCAPG is a prognostic biomarker associated with vascular invasion in hepatocellular carcinoma.
    Guo ZY, Zhu ZT.
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7238-7251. PubMed ID: 34919223
    [Abstract] [Full Text] [Related]

  • 23. A five-miRNA expression signature predicts survival in hepatocellular carcinoma.
    Liu G, Wang H, Fu JD, Liu JY, Yan AG, Guan YY.
    APMIS; 2017 Jul; 125(7):614-622. PubMed ID: 28430373
    [Abstract] [Full Text] [Related]

  • 24. Methylation-mediated repression of microRNA-129-2 suppresses cell aggressiveness by inhibiting high mobility group box 1 in human hepatocellular carcinoma.
    Liu Z, Dou C, Yao B, Xu M, Ding L, Wang Y, Jia Y, Li Q, Zhang H, Tu K, Song T, Liu Q.
    Oncotarget; 2016 Jun 14; 7(24):36909-36923. PubMed ID: 27191994
    [Abstract] [Full Text] [Related]

  • 25. A novel multidimensional signature predicts prognosis in hepatocellular carcinoma patients.
    Wang S, Zhang JH, Wang H, Yang L, Hong S, Yu B, Guo JC, Liu J, Zhu YB.
    J Cell Physiol; 2019 Jul 14; 234(7):11610-11619. PubMed ID: 30480822
    [Abstract] [Full Text] [Related]

  • 26. miR-363-5p as potential prognostic marker for hepatocellular carcinoma indicated by weighted co-expression network analysis of miRNAs and mRNA.
    Zhang J, Fan J, Zhou C, Qi Y.
    BMC Gastroenterol; 2017 Jun 20; 17(1):81. PubMed ID: 28637446
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
    Zhang MH, Niu H, Li Z, Huo RT, Wang JM, Liu J.
    Cancer Biomark; 2018 Jun 20; 23(1):33-43. PubMed ID: 29991125
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
    Zhao QJ, Zhang J, Xu L, Liu FF.
    World J Gastroenterol; 2018 Aug 14; 24(30):3426-3439. PubMed ID: 30122881
    [Abstract] [Full Text] [Related]

  • 36. MicroRNA-194 acts as a prognostic marker and inhibits proliferation in hepatocellular carcinoma by targeting MAP4K4.
    Zhao Y, Li F, Zhang X, Liu A, Qi J, Cui H, Zhao P.
    Int J Clin Exp Pathol; 2015 Aug 14; 8(10):12446-54. PubMed ID: 26722431
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.